NO20074404L - Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid - Google Patents
Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acidInfo
- Publication number
- NO20074404L NO20074404L NO20074404A NO20074404A NO20074404L NO 20074404 L NO20074404 L NO 20074404L NO 20074404 A NO20074404 A NO 20074404A NO 20074404 A NO20074404 A NO 20074404A NO 20074404 L NO20074404 L NO 20074404L
- Authority
- NO
- Norway
- Prior art keywords
- microcrystalline
- quinolin
- indol
- ylmethyl
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504150.4A GB0504150D0 (en) | 2005-03-01 | 2005-03-01 | Microcrystalline material |
| PCT/GB2006/000704 WO2006092579A1 (en) | 2005-03-01 | 2006-03-01 | Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074404L true NO20074404L (no) | 2007-10-25 |
Family
ID=34430394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074404A NO20074404L (no) | 2005-03-01 | 2007-08-29 | Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100041699A1 (xx) |
| EP (1) | EP1856094A1 (xx) |
| JP (1) | JP2008531668A (xx) |
| KR (1) | KR20070107184A (xx) |
| CN (1) | CN101133047A (xx) |
| AU (1) | AU2006219689A1 (xx) |
| BR (1) | BRPI0607423A2 (xx) |
| CA (1) | CA2600891A1 (xx) |
| GB (1) | GB0504150D0 (xx) |
| IL (1) | IL185453A0 (xx) |
| MX (1) | MX2007010588A (xx) |
| NO (1) | NO20074404L (xx) |
| NZ (1) | NZ561246A (xx) |
| RU (1) | RU2007132203A (xx) |
| WO (1) | WO2006092579A1 (xx) |
| ZA (1) | ZA200707233B (xx) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| PL2051962T3 (pl) | 2006-08-07 | 2012-03-30 | Actelion Pharmaceuticals Ltd | Pochodne kwasu (3-amino-1,2,3,4-tetrahydro-9h-karbazol-9-ilo)-octowego |
| WO2009061730A2 (en) | 2007-11-05 | 2009-05-14 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| CN101932571B (zh) | 2008-01-18 | 2014-04-23 | 奥克萨根有限公司 | 具有crth2拮抗活性的化合物 |
| WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
| US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| WO2011108534A1 (ja) * | 2010-03-01 | 2011-09-09 | Shinozawa Takao | プロスタグランディンＤ２とその代謝物およびクレアチニンの分析による筋萎縮性側索硬化症（ＡＬＳ）の診断方法、治療における薬物の有効性を評価する方法および尿中のｔＰＧＤＭ濃度を推測するシステム |
| US8697869B2 (en) | 2010-03-22 | 2014-04-15 | Actelion Pharmaceuticals Ltd. | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| LT2697223T (lt) | 2011-04-14 | 2016-10-10 | Actelion Pharmaceuticals Ltd. | 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indolacto rūgšties dariniai ir jų, kaip prostaglandino d2 receptoriaus moduliatorių, panaudojimas |
| GB201121557D0 (en) * | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| PL3119779T3 (pl) | 2014-03-17 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2 |
| AU2015233046A1 (en) | 2014-03-18 | 2016-11-03 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| AU2016323262B2 (en) | 2015-09-15 | 2020-11-19 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| MA54596A (fr) | 2018-12-27 | 2022-04-06 | Chiesi Farm Spa | Composition pharmaceutique comprenant des agglomérats sphériques de timapiprant |
| CN113975272A (zh) * | 2021-11-29 | 2022-01-28 | 西安交通大学 | 吲哚乙酸（iaa）在制备预防或治疗炎症性肠病药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
-
2005
- 2005-03-01 GB GBGB0504150.4A patent/GB0504150D0/en not_active Ceased
-
2006
- 2006-03-01 BR BRPI0607423A patent/BRPI0607423A2/pt not_active IP Right Cessation
- 2006-03-01 JP JP2007557577A patent/JP2008531668A/ja active Pending
- 2006-03-01 MX MX2007010588A patent/MX2007010588A/es not_active Application Discontinuation
- 2006-03-01 WO PCT/GB2006/000704 patent/WO2006092579A1/en active Application Filing
- 2006-03-01 KR KR1020077022388A patent/KR20070107184A/ko not_active Application Discontinuation
- 2006-03-01 NZ NZ561246A patent/NZ561246A/en unknown
- 2006-03-01 CN CNA2006800067626A patent/CN101133047A/zh active Pending
- 2006-03-01 RU RU2007132203/04A patent/RU2007132203A/ru unknown
- 2006-03-01 US US11/817,399 patent/US20100041699A1/en not_active Abandoned
- 2006-03-01 CA CA002600891A patent/CA2600891A1/en not_active Abandoned
- 2006-03-01 AU AU2006219689A patent/AU2006219689A1/en not_active Abandoned
- 2006-03-01 EP EP06709928A patent/EP1856094A1/en not_active Withdrawn
-
2007
- 2007-08-22 IL IL185453A patent/IL185453A0/en unknown
- 2007-08-27 ZA ZA200707233A patent/ZA200707233B/xx unknown
- 2007-08-29 NO NO20074404A patent/NO20074404L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008531668A (ja) | 2008-08-14 |
| AU2006219689A1 (en) | 2006-09-08 |
| MX2007010588A (es) | 2007-10-23 |
| IL185453A0 (en) | 2008-01-06 |
| WO2006092579A1 (en) | 2006-09-08 |
| NZ561246A (en) | 2009-09-25 |
| GB0504150D0 (en) | 2005-04-06 |
| EP1856094A1 (en) | 2007-11-21 |
| CA2600891A1 (en) | 2006-09-08 |
| CN101133047A (zh) | 2008-02-27 |
| ZA200707233B (en) | 2008-11-26 |
| AU2006219689A2 (en) | 2006-09-08 |
| US20100041699A1 (en) | 2010-02-18 |
| RU2007132203A (ru) | 2009-04-10 |
| KR20070107184A (ko) | 2007-11-06 |
| BRPI0607423A2 (pt) | 2016-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074404L (no) | Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid | |
| UA90706C2 (ru) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний | |
| NO20080784L (no) | Histondeacetylaseinhibitorer | |
| EA200801381A1 (ru) | Производные пиримидина | |
| TNSN07463A1 (en) | Process for the synthesis of organic compounds | |
| NO20076660L (no) | Fremgangsmate for fremstilling av rosuvastatin og mellomprodukter | |
| NO20053340D0 (no) | Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1). | |
| CY1111151T1 (el) | Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος | |
| TW200640912A (en) | Novel processes for the preparation of a 2H-chromene | |
| MX2009004154A (es) | Purinas como inhibidores de pkc-theta. | |
| NO20082116L (no) | Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse | |
| DK1562976T3 (da) | Syntese af estetrol via estron-afledte steroider | |
| NO20081621L (no) | Tetrahydrokinoliner, syntese og intermediater | |
| NO20074623L (no) | Fremgangsmate for peptidsyntese | |
| NO20080468L (no) | Diazepinokinoliner, synteser av disse samt intermediater | |
| NO20075618L (no) | Novel compounds as GLP-1 Agonists | |
| DK1877370T3 (da) | Fremgangsmåde til fremstilling af hydrazon-derivater | |
| HUP0401486A2 (hu) | Eljárás piridinvegyületek előállítására | |
| AR064306A1 (es) | Antagonistas del receptor de angiotensina ii | |
| NO20072551L (no) | Fremgangsmate for fremstilling av purinforbindelser | |
| NO20074101L (no) | Isolering av CCI-779 fra morvaesker | |
| WO2007085651A8 (en) | Process for the stereoselective preparation of alcohols from alpha, beta- insaturated compounds | |
| DE602007009367D1 (de) | Yl)-n-methylbenzylamin | |
| DK1434870T3 (da) | Enzymatisk fremgangsmåde til fremstilling af substitueret 2-amino-3-(2-amino-phenylsulfanyl)-propionsyre | |
| NO20080607L (no) | Fremgangsmate for fremstilling av losartan og nye mellomprodukter som er anvendelige i en slik fremgangsmate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |